Sask ends year with $182M operating surplus

$182    Dan convert $182

Bluejay Therapeutics, a San Mateo, CA-based company which specializes in the development of novel therapeutics, raised $182M in Series C

After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million Al Jasser underscored its pivotal role in global development, with over US$182 billion invested in more than 12,000 projects benefiting millions

दुनिया का सबसे लकी नंबर Al Jasser underscored its pivotal role in global development, with over US$182 billion invested in more than 12,000 projects benefiting millions Sionna Therapeutics secures $182M Series C led by Enavate Sciences, advancing CF treatments with strategic investor support